Kasada to Develop a Dual Branded Hotel Within the Largest Retail Led Mixed Use Development in Côte d’Ivoire

Kasada, the leading independent real estate private equity platform dedicated to hospitality in sub-Saharan Africa, announced today that it will build a new dual-branded hotel in Abidjan within the largest retail-led mixed-use development currently being developed by HCCP. The complex, scheduled to open in 2024, will seek to be certified EDGE, the World Bank’s green building certification program, and will boast over 150 hotel keys, a shopping center with over 60 stores, restaurants, a mini entertainment park, offices, a co-working space, and a clinic.

Olivier Granet, Kasada’s Managing Partner and CEO, said: “We are proud of bringing to Angré’s district its very first international branded hotels and developing a project that will not only benefit our clients but also the local community. Through this greenfield program in this unique location, we demonstrate once more the innovative dynamics of Kasada.”

For this greenfield project in West Africa, Kasada has chosen to work with an innovative investment and development company that has a proven institutional track record. HCCP has previously successfully developed Cosmos Yopougon, a Grade A shopping center opened in 2018 in Abidjan’s largest municipality, that has been the shopping center with the highest footfall in Côte d’Ivoire since 2019.

With a strong commitment to incorporating the highest ESG standards into their projects, Kasada will ensure that the construction of the greenfield hotels and their operations meet the strictest international environmental and social standards. This will include reduced water consumption as well as efficient energy and waste management.

David Damiba, Kasada’s Managing Partner and CIO, added: “We look forward to the execution of this new expansion in Abidjan, a city where we have committed significant capital to date which testifies to our strong belief in the country’s robust macroeconomic outlook. With this combo hotel, we are targeting the economy and extended stay segment to provide an attractive offer at the right price, in the heart of a high-density area.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version